Drug · CHEMBL606
MISOPROSTOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MISOPROSTOL. Drugs and targets, record CHEMBL606. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL606
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGER3 | Prostaglandin E2 receptor EP3 subtype | Prostanoid EP3 receptor agonist | AGONIST | https://conductscience.org/library/genes/5733 |
Source ChEMBL
Diseases34
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 34Source Open Targets
See all 34 diseasesTrials458
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01127581 | Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery | Phase 3 | 1,358 | 2014-03-07 | misoprostol | Its name | ClinicalTrials.gov |
| NCT00308711 | Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor | Phase 3 | 1,308 | 2010-02-19 | misoprostol | Its name | ClinicalTrials.gov |
| NCT02083107 | Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss | Phase 2/3 | 636 | 2014-06-27 | misoprostol | Its name | ClinicalTrials.gov |
| NCT01916681 | Foley OR MisO for the Management of Induction | 491 | 2016-12-21 | misoprostol | Its name | ClinicalTrials.gov | |
| NCT00828711 | Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor | Phase 2 | 374 | 2014-04-21 | misoprostol | Its name | ClinicalTrials.gov |
| NCT00906347 | A Trial of Oral Misoprostol for Labor Augmentation | Phase 4 | 350 | 2012-11-07 | misoprostol | Its name | ClinicalTrials.gov |
| NCT03670836 | Comparison of Misoprostol Ripening Efficacy With Dilapan | Phase 4 | 307 | 2024-07-19 | misoprostol | Its name | ClinicalTrials.gov |
| NCT01751087 | Cervical Preparation Before Dilation and Evacuation | 300 | 2016-02-24 | misoprostol | Its name | ClinicalTrials.gov | |
| NCT02012491 | Comparative Effectiveness of Pregnancy Failure Management Regimens | Phase 3 | 300 | 2018-12-21 | misoprostol | Its name | ClinicalTrials.gov |
| NCT02408315 | Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE) | Phase 3 | 300 | 2019-07-09 | misoprostol | Its name | ClinicalTrials.gov |
1 to 10 of 458
See all 458 trialsComparisons in its trials156
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| MVI 200 vs Dinoprostone Vaginal Insert (DVI): serious adverse events | 130 of 678 | 107 of 680 | 1,358 | NCT01127581 | Trial comparisons |
| Misoprostol Augmentation vs Oxytocin Augmentation: Maternal Chorioamnionitis | 28 of 176 | 32 of 174 | 350 | NCT00906347 | Trial comparisons |
| Misoprostol Augmentation vs Oxytocin Augmentation: Maternal Hypovolemia Requiring Blood Transfusion | 6 of 176 | 2 of 174 | 350 | NCT00906347 | Trial comparisons |
| Misoprostol Augmentation vs Oxytocin Augmentation: Uterine Tachysystole | 50 of 176 | 41 of 174 | 350 | NCT00906347 | Trial comparisons |
| Misoprostol Augmentation vs Oxytocin Augmentation: serious adverse events | 1 of 176 | 2 of 174 | 350 | NCT00906347 | Trial comparisons |
| Dilapan Group vs Misoprostol Group: Percentage of Women Who Developed Chorioamnionitis | 12 of 151 | 10 of 152 | 303 | NCT03670836 | Trial comparisons |
| Dilapan Group vs Misoprostol Group: Percentage of Women Who Developed Postpartum Hemorrhage | 1 of 151 | 3 of 152 | 303 | NCT03670836 | Trial comparisons |
| Dilapan Group vs Misoprostol Group: Number of Participants With Cesarean Deliveries | 41 of 151 | 42 of 152 | 303 | NCT03670836 | Trial comparisons |
| Dilapan Group vs Misoprostol Group: Percentage of Women Delivering Vaginally in 24 Hours After the Initiation of Intervention | 62 of 151 | 58 of 152 | 303 | NCT03670836 | Trial comparisons |
| Dilapan Group vs Misoprostol Group: Percentage of Newborns With Neonatal Intensive Care Unit (NICU) Admission Within 14 Days After Study Intervention | 9 of 151 | 8 of 152 | 303 | NCT03670836 | Trial comparisons |
1 to 10 of 156
See all 156 comparisons in its trialsPapers from its trials240
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Symbol Coding | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL606
GET https://conductscience.org/api/drugs/v1/CHEMBL606/diseases?page=2